Ionis Pharmaceuticals (NASDAQ:IONS) PT Raised to $53.00 at Stifel Nicolaus

Ionis Pharmaceuticals (NASDAQ:IONSFree Report) had its target price hoisted by Stifel Nicolaus from $50.00 to $53.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a hold rating on the stock.

Several other research analysts have also recently weighed in on IONS. Sanford C. Bernstein upgraded Ionis Pharmaceuticals from an underperform rating to a market perform rating and set a $44.00 price target for the company in a research report on Friday, June 14th. Wells Fargo & Company decreased their target price on shares of Ionis Pharmaceuticals from $85.00 to $82.00 and set an overweight rating for the company in a research note on Wednesday, May 8th. Needham & Company LLC restated a buy rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, June 3rd. William Blair reiterated an outperform rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Oppenheimer raised their target price on Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an outperform rating in a research report on Tuesday, April 9th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $58.64.

Read Our Latest Analysis on IONS

Ionis Pharmaceuticals Stock Performance

IONS opened at $47.66 on Thursday. The company has a current ratio of 7.37, a quick ratio of 7.28 and a debt-to-equity ratio of 4.15. Ionis Pharmaceuticals has a 12-month low of $35.95 and a 12-month high of $54.44. The firm has a 50 day moving average of $40.55 and a two-hundred day moving average of $44.82. The firm has a market capitalization of $6.96 billion, a PE ratio of -17.85 and a beta of 0.35.

Ionis Pharmaceuticals (NASDAQ:IONSGet Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.12. The company had revenue of $119.00 million during the quarter, compared to the consensus estimate of $131.42 million. Ionis Pharmaceuticals had a negative net margin of 49.49% and a negative return on equity of 107.64%. The firm’s quarterly revenue was down 9.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.87) earnings per share. On average, analysts anticipate that Ionis Pharmaceuticals will post -3.91 EPS for the current year.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Joseph Baroldi sold 4,006 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total transaction of $166,649.60. Following the sale, the executive vice president now owns 19,631 shares of the company’s stock, valued at approximately $816,649.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Ionis Pharmaceuticals news, Director Joseph Klein III sold 6,000 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $42.71, for a total value of $256,260.00. Following the completion of the sale, the director now directly owns 16,346 shares in the company, valued at approximately $698,137.66. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Joseph Baroldi sold 4,006 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $41.60, for a total value of $166,649.60. Following the transaction, the executive vice president now owns 19,631 shares in the company, valued at approximately $816,649.60. The disclosure for this sale can be found here. 2.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 2.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,378 shares of the company’s stock worth $424,000 after purchasing an additional 202 shares during the period. Grandfield & Dodd LLC boosted its stake in Ionis Pharmaceuticals by 0.7% during the fourth quarter. Grandfield & Dodd LLC now owns 33,104 shares of the company’s stock worth $1,675,000 after buying an additional 242 shares during the period. Treasurer of the State of North Carolina increased its position in shares of Ionis Pharmaceuticals by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 62,532 shares of the company’s stock valued at $2,836,000 after acquiring an additional 310 shares during the last quarter. Fifth Third Bancorp raised its stake in shares of Ionis Pharmaceuticals by 3.8% in the 1st quarter. Fifth Third Bancorp now owns 9,633 shares of the company’s stock valued at $418,000 after acquiring an additional 351 shares during the period. Finally, M&T Bank Corp lifted its holdings in shares of Ionis Pharmaceuticals by 7.8% in the 4th quarter. M&T Bank Corp now owns 5,188 shares of the company’s stock worth $263,000 after acquiring an additional 376 shares during the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Company Profile

(Get Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Recommended Stories

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.